Skip to main content
Saturday 21 November 2026
BlueSky linkedin youtube
header links
  • Get Newsletters
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Equity and Sustainability
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Rare Disease
    • GLP-1
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO
    • BIO-Europe
    • C-Suite Innovators
    • ESMO
    • Frontiers Health
    • JP Morgan
    • Global Policy Insights
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
youtube linkedin BlueSky
Sign in

Pfizer

News
EMA starts review of Xtandi in hormone-sensitive prostate cancer

EMA starts review of Xtandi in hormone-sensitive prostate ca...

News
Scotland backs Pfizer’s Ibrance for breast cancer

Scotland backs Pfizer’s Ibrance for breast cancer

News
Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’

Array, Pierre Fabre bowel cancer therapy ‘could replace chem...

News
NICE clears front-line NHS use for Pfizer’s lung cancer drug Vizimpro

NICE clears front-line NHS use for Pfizer’s lung cancer drug...

News
HIV budding Color

ViiV's Dovato HIV pill approved in EU

ViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over patients with a more convenient treatment approach.

News
img_1029

Lawmaker weighs in on Gottlieb switch to industry

  • Load more results

Editor's Picks

  1. RevMed hails first-line data with pancreatic cancer drug
  2. J&J cuts $3.3bn deal to buy eye drug developer Ollin
  3. UK modernises gene therapy definition in regulatory revamp
  4. Isomorphic Labs raises $5bn in massive third round
  5. UK sets 2029 timeline to end Palantir's NHS contract
News
Dr Rafal Kaminski

Angelini Pharma's R&D chief heads for the exit

Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png
Sales & Marketing
Securing your ROI: Turning post-acquisition integration into operational and strategic value
Sponsored

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Axtria Ignite 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Get Newsletters

 
 
youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company